Bottom line
Is RSVAX a good fund? The bottom line
RSVAX is the Class A share class of Victory RS Value Fund, a managed large value mutual fund from Victory Capital.
It charges 1.3% — about $130 a year on every $10,000 invested, more expensive than 83% of large value funds we track.
It returned −1.4% over one year, +8.1% a year over five years, +8.2% a year over ten (as of Dec 31, 2025, per its prospectus).
With $253 million in net assets and 61 holdings, its largest position is Globe Life Inc. (4.4%) and the top 10 make up 26.8% of the portfolio.
This share class carries a front-end sales charge of up to 5.75%; a no-load class or ETF alternative can avoid it.
What to watch
- Expensive for its category (1.3%)
- 5-year return in the bottom quarter of its category
- Front-end sales load up to 5.75%
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What RSVAX invests in
The Victory RS Value Fund (the Fund) seeks to provide long-term capital appreciation.
The Adviser pursues the Funds investment objective by investing, under normal circumstances, principally in equity securities of companies with market capitalizations between $1 billion and 120% of the market capitalization of the largest company included in the Russell Midcap Index (Index) (currently, approximately $139.8 billion, based on the size of the largest company in the Index on March 31, 2026) that the Adviser believes are undervalued. The size of companies in the Index changes with market conditions and the composition of the Index. The Fund typically invests in equity securities of U.S. companies but may also invest any portion of its assets in foreign securities, including depositary receipts such as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The Fund holds a relatively few number of securities; and as a result of the Advisers investment…
From the fund's prospectus (filed Apr 29, 2026).
RSVAX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| RSVAX | −1.4% | +8.1% | +8.2% |
| Large Value median | +13.6% | +11.3% | +10.2% |
Source: Fund prospectus, as of Dec 31, 2025
What RSVAX costs
On a $10,000 investment, RSVAX's 1.3% expense ratio costs about $130 a year. The prospectus estimates $2,082 in total costs over 10 years (assuming 5% annual returns). The median large value fund charges 0.81%.
RSVAX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Globe Life Inc. | 4.40% |
| 2 | Teva Pharmaceutical Industries Limited... | 3.05% |
| 3 | Firstenergy Corp. | 2.72% |
| 4 | Ametek, Inc. | 2.70% |
| 5 | Nnn REIT, Inc. | 2.56% |
| 6 | Centerpoint Energy, Inc. | 2.44% |
| 7 | Dover Corporation | 2.37% |
| 8 | Marketaxess Holdings Inc. | 2.21% |
| 9 | The Timken Company | 2.20% |
| 10 | Littelfuse, Inc. | 2.13% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 26.8% of the fund. See all top 25 holdings and asset mix →